Camlin Fine Sciences Limited , a prominent player in the fine chemicals industry, has announced an extension to the completion timeline for its proposed acquisition of a majority stake in Vinpai S.A. The new deadline is set for November 30, 2025, pushed back from the earlier target of September 30, 2025.

Reasons for the Delay

The company attributed the delay to documentation requirements for foreign sellers involved in the transaction. Specifically, the foreign national sellers needed to obtain Permanent Account Numbers (PANs), a prerequisite for preferential allotment under Securities and Exchange Board of India (SEBI) regulations.

Progress and Next Steps

According to the latest LODR (Listing Obligations and Disclosure Requirements) filing by Camlin Fine Sciences, the foreign sellers have successfully obtained their PANs. This development paves the way for the next phase of the acquisition process.

Upcoming Approvals

Camlin Fine Sciences is now seeking approval from its Board of Directors and shareholders to issue equity shares through preferential allotment. This issuance is intended as payment for acquiring the majority stake in Vinpai via a share swap arrangement.

Background of the Acquisition

The proposed acquisition was initially disclosed on February 24, 2025, when Camlin Fine Sciences executed a Share Purchase Agreement (SPA) with certain significant shareholders of Vinpai, including its founders. A subsequent update on June 25, 2025, had set the expected completion date as September 30, 2025.

Regulatory Compliance

The company has assured stakeholders that it is adhering to all necessary regulatory requirements. In its LODR filing, Camlin Fine Sciences stated that relevant details as mandated under Regulation 30 of the SEBI Listing Regulations, read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, were provided in their prior disclosure on February 24, 2025.

This extension in the acquisition timeline highlights the complexities involved in cross-border transactions, particularly when navigating regulatory requirements. As Camlin Fine Sciences progresses with its plans to acquire a majority stake in Vinpai S.A., investors and industry observers will be keenly watching for further developments in this strategic move.

Camlin Fine Sciences Limited has announced a crucial board meeting scheduled for September 29, 2025, to deliberate on a significant strategic move. The company is set to consider issuing equity shares through preferential allotment as part of a share swap arrangement, aiming to acquire a majority stake in Vinpai S.A.

Key Highlights

• Board Meeting Date: September 29, 2025
• Purpose: To consider and potentially approve the issuance of equity shares via preferential allotment
• Acquisition Target: Majority stake in Vinpai S.A.
• Method: Share swap arrangement
• Approval Process: Subject to shareholder approval through postal ballot

Trading Window Closure

In compliance with regulatory requirements, Camlin Fine Sciences has implemented a trading window closure:

• Closure Period: September 24, 2025, until 48 hours after the board meeting concludes
• Applicable to: Insiders, designated persons, and their immediate relatives

Background and Regulatory Compliance

The upcoming board meeting is a continuation of Camlin Fine Sciences' strategic plans, following previous disclosures made in February and June 2025 regarding the Vinpai acquisition. The company has emphasized that the proposed preferential issue for the share swap will be conducted in accordance with:

• The Companies Act, 2013, and its associated rules
• Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018
• Other applicable laws and regulatory approvals

Shareholder Approval Process

If the board approves the proposal, Camlin Fine Sciences intends to initiate a postal ballot process to seek shareholder approval for the preferential issue related to the share swap. This step underscores the company's commitment to transparent corporate governance and shareholder engagement in major strategic decisions.

Market Implications

The proposed acquisition of a majority stake in Vinpai S.A. through a share swap arrangement could potentially strengthen Camlin Fine Sciences' market position and expand its operational capabilities. Investors and market analysts will be closely watching the outcome of the September 29 board meeting and the subsequent shareholder approval process.

Stakeholders are advised to stay tuned for further updates and official announcements from the company regarding the progress of the Vinpai acquisition and its potential impact on Camlin Fine Sciences' future growth trajectory.